PARP inhibitors (PARPi) are now standard therapeutic agents for patients with HER2-negative advanced breast cancer and a gBRCA1/2 m based on phase III trials showing improvement in progression-free survival (PFS) [5, 6]. This evidence concerns the gene ERBB2 and breast carcinoma.